Undisclosed ImmTAAI candidates
Autoimmune Diseases
PreclinicalResearch
Key Facts
About Immunocore
Immunocore is a UK-based, publicly traded biotech focused on developing transformative T cell receptor-based immunotherapies. Its core achievement is the 2022 launch of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, for metastatic uveal melanoma. The company is advancing a broad pipeline of bispecific candidates across oncology, virology (HBV, HIV), and autoimmunity using its modular ImmTAX platform, positioning it as a leader in next-generation targeted immunomodulation.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| ARGX-118 | Argenx | Phase 1 |
| Adalimumab biosimilar (IBI303) | Innovent Biologics | Approved |
| Hulio (Adalimumab) | Biocon | Approved |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Bispecifics | Shattuck Labs | IND-Enabling |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |